Publicacións nas que colabora con Óscar Mauricio Bautista Aguilera (20)

2022

  1. N-Hydroxy-N-Propargylamide Derivatives of Ferulic Acid: Inhibitors of Cholinesterases and Monoamine Oxidases

    Molecules, Vol. 27, Núm. 21

2021

  1. Tacrines as Therapeutic Agents for Alzheimer's Disease. V. Recent Developments

    Chemical Record, Vol. 21, Núm. 1, pp. 162-174

2020

  1. Acetylcholinesterase inhibition of diversely functionalized quinolinones for alzheimer’s disease therapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 11, pp. 1-20

  2. Automated Synthesis of New Quinoxalinetacrines

    ChemistrySelect, Vol. 5, Núm. 21, pp. 6491-6493

  3. In Vitro and in Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases

    ACS Chemical Neuroscience, Vol. 11, Núm. 22, pp. 3793-3801

  4. Triazolopyridopyrimidine: A new scaffold for dual-target small molecules for Alzheimer's disease therapy

    Molecules, Vol. 25, Núm. 14

2018

  1. Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6937-6943

2017

  1. Design, Synthesis and Biological Evaluation of Potent Antioxidant 1-(2,5-Dimethoxybenzyl)-4-arylpiperazines and N-Azolyl Substituted 2-(4-Arylpiperazin-1-yl)

    ChemistrySelect, Vol. 2, Núm. 13, pp. 3854-3859

  2. Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases

    Angewandte Chemie - International Edition, Vol. 56, Núm. 41, pp. 12765-12769

2016

  1. N-Benzylpiperidine Derivatives as α7 Nicotinic Receptor Antagonists

    ACS Chemical Neuroscience, Vol. 7, Núm. 8, pp. 1157-1165

  2. Synthesis and Biological Assessment of Racemic Benzochromenopyrimidinimines as Antioxidant, Cholinesterase, and Aβ1−42Aggregation Inhibitors for Alzheimer's Disease Therapy

    ChemMedChem, pp. 1318-1327

  3. Synthesis and biological evaluation of benzochromenopyrimidinones as cholinesterase inhibitors and potent antioxidant, non-hepatotoxic agents for Alzheimer's disease

    Molecules, Vol. 21, Núm. 5

  4. The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators

    Journal of Medicinal Chemistry, Vol. 59, Núm. 21, pp. 9967-9973

2015

  1. Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer’s disease

    Mini-Reviews in Medicinal Chemistry, Vol. 15, Núm. 8, pp. 648-658

  2. Predicting targets of compounds against neurological diseases using cheminformatic methodology

    Journal of Computer-Aided Molecular Design, Vol. 29, Núm. 2, pp. 183-198

2014

  1. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 75, pp. 82-95

  2. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 80, pp. 543-561

  3. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease: Design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids

    Drug Design, Development and Therapy, Vol. 8, pp. 1893-1910

  4. N-methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor

    Journal of Medicinal Chemistry, Vol. 57, Núm. 24, pp. 10455-10463

  5. Wnt signaling pathway, a potential target for Alzheimer's disease treatment, is activated by a novel multitarget compound ASS234

    CNS Neuroscience and Therapeutics